Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2023
PHARMAC’s new equity policy
6 December 2023 - PHARMAC is drafting its first Equity Policy which outlines the mahi PHARMAC does, can do, or needs ...
Posted by Michael Wonder on 06 Dec 2023
Secukinumab for the treatment of patients with moderate to severe hidradenitis suppurativa (final guidance)
6 December 2023 - NICE has published final evidence-based recommendations on the use of secukinumab (Cosentyx) for the treatment of ...
Posted by Michael Wonder on 06 Dec 2023
Being more strategic and coordinated when we collaborate
6 December 2023 - Like other health entities, PHARMAC is busy working on strategies to meet the requirements of the ...
Posted by Michael Wonder on 05 Dec 2023
Government sends mixed message to global life science investors
5 December 2023 - The Government has published new terms for the Statutory Scheme for branded medicines, maintaining sales rebates ...
Posted by Michael Wonder on 04 Dec 2023
Vosoritide in achondroplasia: indication of an additional clinical benefit for children aged two and over
1 December 2023 - Two small RCTs with children of different ages together make it possible to make one statement: the ...
Posted by Michael Wonder on 04 Dec 2023
PHARMAC publishes minutes from August 2023 PTAC meeting
3 December 2023 - The meeting was held on 17-18 August 2023. After looking at the agenda, one asks why did ...
Posted by Michael Wonder on 03 Dec 2023
Agenda for the December 2023 PBAC intracycle meeting
1 December 2023 - The agenda for the December 2023 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 02 Dec 2023
Keytruda is a step closer to being available for more cancers listed on the PBS
1 December 2023 - Thousands of cancer patients in Australia will benefit from a major change that would see Keytruda offered ...
Posted by Michael Wonder on 02 Dec 2023
Steve Maharey quits as chair of PHARMAC, ACC
1 December 2023 - Both the Health Minister Dr Shane Reti and Minister for ACC Matt Doocey announced today they ...
Posted by Michael Wonder on 02 Dec 2023
PHARMAC making progress on action plan to enhance organisational culture
1 December 2023 - PHARMAC is making progress to enhance the organisational culture with all immediate tasks in the action ...
Posted by Michael Wonder on 02 Dec 2023
Updates to the HTA Policy and Methods Review Reference Committee (1 December 2023)
1 December 2023 - To ensure that the Reference Committee has sufficient time to consider the extensive and valuable input ...
Posted by Michael Wonder on 01 Dec 2023
Pembrolizumab with trastuzumab and chemotherapy for the first-line treatment of patients with advanced HER2 positive gastric or gastro-oesophageal junction cancer
1 December 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Dec 2023
New frontier will lead to better health outcomes
30 November 2023 - The Government has today tabled its response to an inquiry considering how to give Australian patients timely ...
Posted by Michael Wonder on 30 Nov 2023
Schedule of Pharmaceutical Benefits - 1 December 2023
1 December 2023 - The December 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Nov 2023
New Zealand Pharmaceutical Schedule - 1 December 2023
1 December 2023 - The December 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...